- Home
- CSCI vs BCDA Comparison
CSCI vs BCDA Comparison
Compare CSCI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- BCDA
- Stock Information
- Founded
- CSCI 1990
- BCDA N/A
- Country
- CSCI Canada
- BCDA United States
- Employees
- CSCI N/A
- BCDA N/A
- Industry
- CSCI
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- BCDA Health Care
- Exchange
- CSCI NYSE
- BCDA Nasdaq
- Market Cap
- CSCI 10.5M
- BCDA 11.0M
- IPO Year
- CSCI 1996
- BCDA N/A
- Fundamental
- Price
- CSCI $3.37
- BCDA $2.15
- Analyst Decision
- CSCI
- BCDA Strong Buy
- Analyst Count
- CSCI 0
- BCDA 1
- Target Price
- CSCI N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CSCI 2.1K
- BCDA 52.3K
- Earning Date
- CSCI 08-12-2025
- BCDA 08-12-2025
- Dividend Yield
- CSCI N/A
- BCDA N/A
- EPS Growth
- CSCI N/A
- BCDA N/A
- EPS
- CSCI N/A
- BCDA N/A
- Revenue
- CSCI $9,030,000.00
- BCDA $3,000.00
- Revenue This Year
- CSCI N/A
- BCDA N/A
- Revenue Next Year
- CSCI N/A
- BCDA N/A
- P/E Ratio
- CSCI N/A
- BCDA N/A
- Revenue Growth
- CSCI 36.51
- BCDA N/A
- 52 Week Low
- CSCI $1.96
- BCDA $1.63
- 52 Week High
- CSCI $7.54
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- BCDA 51.13
- Support Level
- CSCI N/A
- BCDA $1.98
- Resistance Level
- CSCI N/A
- BCDA $2.45
- Average True Range (ATR)
- CSCI 0.00
- BCDA 0.17
- MACD
- CSCI 0.00
- BCDA 0.01
- Stochastic Oscillator
- CSCI 0.00
- BCDA 53.19
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).